In a significant development in the expanding medicinal cannabis sector, leading brand Cannarma has secured an undisclosed amount in pre-seed funding. The funding round, led by Praveen Kaushik of Zero to One Fund, valued the company at Rs 17 crore ($2.04 million) before the investment. Amity Innovation Incubator also participated in supporting this promising startup. The funding aims to fuel various growth strategies, including bolstering engagement with current customers, entering new markets, and advancing technological capabilities. Cannarma aims to extend its presence to encompass over 10,000 medical stores, clinics, and hospitals across India as part of its strategic vision.

Established in August 2022 by Rohit Chauhan and Keshav Agarwal, Cannarma operates as a research and development entity with authorization from the Department of Ayush. This authorization enables the brand to produce and distribute various Ayurvedic products, including CBD oil, hemp seed oil, and medicinal cannabis, all formulated with a dedicated focus on utilizing exclusively natural components. The startup, headquartered in Delhi, has established partnerships with governmental bodies in Himachal Pradesh, India. Cannarma asserts that their collaborations align with developing regulations concerning hemp cultivation for medicinal, industrial, and scientific objectives, aiming to unlock cannabis' medicinal attributes for patient care while simultaneously generating revenue for the state through hemp-derived goods.

Cannarma's product lineup demonstrates proven efficacy in addressing a wide spectrum of health concerns, encompassing issues such as the Opioid crisis, Cholesterol, Blood Pressure, Diabetes, sleeping disorders, Anxiety, Depression, Arthritis pain, Chronic Pain, Neuropathic Pain, Epilepsy, Parkinson's, and mitigating the side effects of Cancer Chemotherapy. The successful pre-seed funding round not only injects capital into Cannarma's growth trajectory but also highlights the increasing acknowledgment and support for advancements in medicinal cannabis research and development. As the company advances, the focus remains on its dedication to innovation, natural constituents, and contributing to the evolving landscape of healthcare solutions.